GXMC
TBPH icon

Global X Management Company’s Theravance Biopharma TBPH Stock Holding History

Global X Management Company’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-81,886
Closed -$2.61M – 551
2014
Q2 		$2.61M Buy
+81,886
New +$2.47M 0.15% 180

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Global X Management Company's TBPH Position: Q3 2014 in Review

Global X Management Company sold out of Theravance Biopharma (TBPH) in Q3 2014, closing a stake of 81,886 shares — an estimated $2.61M sold.

Global X Management Company first reported a position in TBPH in Q2 2014 and held it in 1 quarter. The position peaked at $2.61M in Q2 2014. 91 funds tracked by Wall St. Rank hold TBPH as of Q3 2014.

  • Global X Management Company reported no remaining Theravance Biopharma position as of Q3 2014 after selling out during the quarter.
  • Global X Management Company sold 81,886 Theravance Biopharma shares in Q3 2014, an estimated $2.61M.
  • Global X Management Company first reported a position in Theravance Biopharma in Q2 2014 and held it in 1 quarter.
  • Global X Management Company's Theravance Biopharma position peaked at $2.61M in Q2 2014.
  • 91 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2014.

Based on Global X Management Company's 13F filing for Q3 2014, filed 4 Nov 2014.